Právní předpis byl sestaven k datu 30.04.2025.
Zobrazené znění právního předpisu je účinné od 01.10.2015.
Nařízení vlády, kterým se mění nařízení vlády č. 463/2013 Sb., o seznamech návykových látek
243/2015 Sb.
Účinnost Čl. III
243
XXXXXXXX XXXXX
xx dne 14. září 2015,
kterým xx mění nařízení xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx xxxxx
Xxxxx xxxxxxxx xxxxx §44c odst. 1 xxxxxx x. 167/1998 Xx., x xxxxxxxxxx látkách a x xxxxx xxxxxxxxx xxxxxxx xxxxxx, xx xxxxx xxxxxx č. 273/2013 Xx.:
Xx. X
Xxxxxxx x. 4 k xxxxxxxx xxxxx č. 463/2013 Sb., o xxxxxxxxx návykových xxxxx, xxx:
"Xxxxxxx č. 4 x xxxxxxxx xxxxx x. 463/2013 Sb.
|
Mezinárodní xxxxxxxxxx xxxxx (XXX) x xxxxxx xxxxxx |
Xxxxx xxxxxxxxxxx xxxxxxxxxx název xxxx obecný název |
Chemický xxxxx xxxxx XXXXX |
Xxxxxxxx |
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx)]xxxxxx}xxxxxxxx |
||
|
XX-2201 |
[1-(5-xxxxxxxxxxx)-1X-xxxxx-3-xx](xxxxxxxx-1-xx)xxxxxxxx |
||
|
5-XX1 |
5-(2-xxxxxxxxxxx)xxxxx |
||
|
XXXXXXX |
X-(xxxxxxxxx-1-xx)-1-xxxxxx-1X-xxxxxxx-3-xxxxxxxxxx |
||
|
xx-XXX |
2-xxxxx-1-(4-xxxxxxxxxxxx)xxxxxx-1-xx |
||
|
xx-XXXX |
1-(4-xxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
||
|
25X-XXXXx |
2-(4-xxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxx |
XXX |
(2XX)-1-(4-xxxx-2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
Xxxxx-Xxxxxxxxx |
1-(8-xxxxxxxxx[1,2x:4,5-x´]xxxxxxx-4-xx)xxxxxx-2-xxxx |
||
|
Xxxxxxx |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx)]xxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxx |
2X-X |
(4-xxx-2,5-xxxxxxxxxxxxxxxxx)xxxx |
|
|
25X-XXXXx |
2-(4-xxxxx-2,5-xxxxxxxxxxxxxx)-X-[(2-xxxxxxxxxxxx)xxxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-2 |
[4-(xxxxxxxxxxxxx)-2,5-xxxxxxxxxxxxxxxxx]xxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
2X-X-7 |
[2,5-xxxxxxxxx-4-(xxxxxxxxXxxxxx)xxxxxxxx]xxxx |
|
|
XX-47,497 |
2-[(1X,3X)-3-xxxxxxxxxxxxxxxxx]-5-(2-xxxxxxxxxxx-2-xx)xxxxx |
||
|
XXX-13 |
(xxxxxxxx-1-xx)[4-(xxxxxxxxx)xxxxxxxx-1-xx]xxxxxxxx |
||
|
XXXX |
1,4-xxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
XXX |
X,X-xxxxxxx-X-[2-(xxxxx-3-xx)xxxxx]xxxx |
|
|
Xxxxxxxxxxxxxxxxxx |
XXX |
(2XX)-1-(2,5-xxxxxxxxxxxxxx)xxxxxx-2-xxxx |
|
|
4,4'-XXXX |
4-xxxxxx-5-(4-xxxxxxxxxxx)-4,5-xxxxxxx-1,3-xxxxxx-2-xxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX |
3-(1,2-xxxxxxxxxxxxxx)-6,6,9-xxxxxxxxx-7,8,9,10-xxxxxxxxxx-6X-xxxxx[x] xxxxxxx-1-xx |
|
|
3,4-XXXX |
1-(3,4-xxxxxxxxxxxxx)-2-(xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX |
X[2-(xxxxx-3-xx (ethyl]-N,N-dimethylamin |
|
|
DOC |
1-(4-chlor-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Dimethoxyethylamfetamin |
DOET |
(2RS)-1-(4-ethyl-2,5-dimethoxyfenyl)propan-2-amin |
|
|
DOl |
1-(4-jod-2,5-dimethoxyfenyl)propan-2-amin |
||
|
Eticyklidin |
PCE |
N-ethyl-1-fenylcyklohexylamin |
|
|
Etryptamin |
3-(2-aminobutyl)indol |
||
|
4-FA |
1-(4-fluorfenyl)propan-2-amin |
||
|
5F-AKB48 |
N-(adamantan-1-yl)-1-(5-fluorpentyl)-1H-indazol-3-karboxamid |
||
|
Flefedron |
1-(4-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
4-FMA |
1-(4-fluorfenyl)-N-methylpropan-2-amin |
||
|
3-FMC |
1-(3-fluorfenyl)-2-(methylamino)propan-1-on |
||
|
5FUR-144 |
[1-(5-fluorpentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyklopropyl)methanon |
||
|
251-NBOMe |
2-(4-jod-2,5-dimethoxyfenyl)-N-[(2-methoxyfenyl)methyl]ethanamin |
||
|
JWH-018 |
(naftalen-1-yl)(1-pentyl-1H-indol-3-yl)methanon |
||
|
JWH-073 |
(1-butyl-1H-indol-3-yl)(naftalen-1-yl)methanon |
||
|
JWH-081 |
(4-methoxynaftalen-1-yl)(1 -pentyl-1H-indol-3-yl)methanon |
||
|
JWH-122 |
(4-methylnaftalen-1-yl)(1-pentyl-1H-indol-3-y)methanon |
||
|
JWH-200 |
[1-(2-morfolinoethyl)-1H-indol-3-yl](naftalen-1-yl)methanon |
||
|
JWH-250 |
2-(2-methoxyfenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-1-on |
||
|
JWH-398 |
(4-chlornaftalen-1-yl)(1-pentyl-1H-indol-3-yl)methanon |
||
|
Kathinon |
(2S)-2-amino-1-fenylpropan-1-on |
||
|
(+)-Lysergid |
LSD, XXX-25 |
(+)-8β-(3,3-xxxxxxxxxxxxxx)-6-xxxxxx-9,10-xxxxxxxxxxxxxxxx |
|
|
4-Xxxxxxxxxxxx |
(2XX)-1-(4-xxxxxxxxxxx)xxxxxx-2-xxxx |
||
|
XXXX |
1-xxxxxx-4-xxxxxxxxxxxxxxx |
||
|
xXXX |
1-(3-xxxxxxxxxx)xxxxxxxxx |
||
|
XXXX |
5,6-(xxxxxxxxxxxxx)xxxxx-2-xxxx |
||
|
XXXX |
1-[3,4-(xxxxxxxxxxxxx)xxxxx]-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
3-XXX |
2-(xxxxxxxxxx)-1-(3-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
4-XXX |
2-(xxxxxxxxxx)-1-(4-xxxxxxxxxxx)-xxxxxx-1-xx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-(4-xxxxxxxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxx |
3,4,5-xxxxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxx |
Xxxxxxx |
(2XX)-1-xxxxx-2-(xxxxxxxxxxx)xxxxxx-1-xx |
|
|
3-XXX |
2-(xxxxxxxxxxx(-1-(3-xxxxxXxxxxx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-1-[5-xxxxxxx-3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxxxx |
(±)-5-xxxxx-4-xxxxxx-4,5-xxxxxxxxxxxxx-2-xxxxx |
||
|
Xxxxxxxxxxxxxxxxxx |
XXXX |
(2XX)-X-xxxxxx-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
3-XxX-XXX |
1-[1-(3-xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxxxxx |
||
|
xxxxxxxxxxxxx |
2-(xxxxxxxxxx)-2-(3-xxxxxxxxxxxx)xxxxxxxxxxxx |
||
|
Xxxxxxxx |
2-(xxxxxxxxxxx)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-1-xx |
||
|
XX-45 |
1-xxxxxxxxxx-4-(1,2-xxxxxxxxxxxx)-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
4-XXX |
(2XX)-1-[4-(xxxxxXxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxx |
1-(xxxxxxxx-2-xx)-2-(xxxxxxxxxx-1-xx)xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxx |
XXX, MDEA |
(2RS)-N-ethyl-1-[3,4-(methylendioxy)fenyllpropan-2-amin |
|
|
Hydroxytenamfetamin |
(2RS)-N-hydroxy-1-[3,4-(methylendioxy)fenyl]propan-2-amin |
||
|
Paraliexyl |
3-hexyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol |
||
|
pentedron |
1-fenyl-2-(methylainino)pentan-1-on |
||
|
pFPP |
1-(4-fluorfenyl)piperazin |
||
|
Methoxyamfetamin |
PMA |
(2RS)-1-(4-methoxyfenyl)propan-2-amin |
|
|
Methoxymetamfetamin |
PMMA |
1-(4-methoxyfenyl)-N-methylpropan-2-amin |
|
|
Psilocybin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-yl-dihydrogen-fosfát |
||
|
Psilocin |
Psilotsin |
3-[2-(dimethylamino)ethyl]-1H-indol-4-ol |
|
|
Rolicyklidin |
PHP, XXXX |
1-(1-xxxxxxxxxxxxxxx)xxxxxxxxxx |
|
|
α-XXX |
1-xxxxx-2-(xxxxxxxxxx-1-xx)-1-xxxxxx-1-xx |
||
|
Xxxxxxxxxx X |
xxxxxx-(2XX,4xX,6xX,7X,9XX,10xXX,10xX)-9-xxxxxxx-2-(xxxxx-3-xx)-6x, 10x-xxxxxxxx-4,10-xxxxxxxxxxxxxxxx-1X-xxxxx[x]xxxxxxxxxx-7-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
XXX, XXX |
(2XX)-1-(2,5-xxxxxxxxx-4-xxxxxxxxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
(2XX)-1-[3,4-(xxxxxxxxxxxxx)xxxxx]xxxxxx-2-xxxx |
|
|
Xxxxxxxxxxxx |
XXX |
1-[1-(2-xxxxxxx)xxxxxxxxxx]xxxxxxxxx |
|
|
XXXXX |
1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX |
Δ6x(10x)-,Δ6x(7)-,Δ7-,Δ8-,Δ10-,Δ9(11)-xxxxxxxxxxxxxxxxxxxx x xxxxxx stereoizomery |
|
|
Trimethoxyamfetamin |
TMA |
(2RS)-1-(3,4,5-trimethoxyfenyl)propan-2-amin |
|
|
Trimethoxyamfetamin-2 |
TMA-2 |
(2RS)-1-(2,4,5-trimethoxyfenyl)propan-2-amin |
|
|
UR-144 |
(1-pentyl-1H-indol-3-yl)-(2,2,3,3-tetramethylcyklopropyl)methanon |
Včetně xxxxxxxxxxxxx xxxxxxxxxxxxxx látek, xx xx xxxxxxxx xxxxxxx, xxxxxxxxx v xxxxx xxxxxxx xx xxxxx případech, xxx xxxx stereaizomery xxxxx xxxxxxxxx podle xxxxxxxxxx xxxxxxxxxx označení x xxxx psychotropních látek xxxxxxxxx x xxxxx xxxxxxx ve xxxxx xxxxxxxxx, xxx xxxxx xxxxxxxxx.".
Čl. II
Toto xxxxxxxx xxxx xxxxxxxx x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx 98/34/ES xx xxx 22. xxxxxx 1998 x postupu xxx poskytování xxxxxxxxx x xxxxxxx xxxxx x technických předpisů x xxxxxxxx xxx xxxxxx informační xxxxxxxxxxx, x platném znění.
Xx. III
Účinnost
Toto nařízení xxxxxx xxxxxxxxx dnem 1. xxxxx 2015.
&xxxx;Xxxxxxxx xxxxx:
Xxx. Xxxxxxx v. x.
&xxxx;Xxxxxxx zdravotnictví:
MUDr. Xxxxxxx, XXX, x. x.
Xxxxxxxxx
Xxxxxx předpis č. 243/2015 Xx. xxxxx xxxxxxxxx xxxx 1.10.2015.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x odkazech xxxx xxxxxxxxxxxxx, xxxxx se xxxx netýká xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.